Sepsis is to blame for the 40-year-old mother's unexpected death. It sheds light on broader maternal healthcare issues for Black women.

Vivacelle Bio and University of Missouri-Kansas City School of Medicine Announce Groundbreaking Results from Phase 2a Clinical Trial of VBI-S for Refractory Hypotension in Severe Septic Shock Patients

Vivacelle Bio Integrates Sub-Saharan Africa Strategy into Series B Financing Round

Feds hope to cut sepsis deaths by hitching Medicare payments to treatment stats

The Lancet Journal - Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2

Hypovolemic Shock Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Pharmazz, Perfusion Medical, Vivacelle Bio

Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients

(BPRW) Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis

Septic Shock Market is Expected to Expand at a Healthy Growth Rate by (2022-2032), States DelveInsight | Key Companies – Adrenomed AG, Vivacelle Bio, Inotrem

Harven DeShield in BizCast HQ

Vivacelle Bio - Biotech Executive Conversations

Sepsis And Septic Shock Treatment Market Hitting New Highs By 2028 | VBI-S: Vivacelle Bio, Nangibotide (LR12): Inotrem, Allocetra: Enlivex Therapeutics

Vivacelle Bio named included in 101 top Illinois Biotechnology Companies and Startups - 2021

Hypovolemic Shock Market: Market Analysis, Leading Companies, Emerging Drugs, Epidemiology Forecast and Competitive Analysis by DelveInsight

World Sepsis Pipeline Insight 2021: Pipeline Product Profiles, Therapeutic Assessment, Pipeline Assessment, Inactive Drugs Assessment, Unmet Needs

Vivacelle Bio Receives $5.3 Million Award from the US Navy for a Clinical Trial of VBI-S for Treatment of Hypovolemia of Septic Shock Due to COVID or other Pathogens

Vivacelle Bio Given the Business Expansion Award by the Metro Chamber Alliance of Greater Fort Wayne

Black Doctor Says He Has Developed Clinical Treatment For COVID-19 Patients That Increases Oxygen Levels

VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients

Vivacelle Bio Provides its Sepsis Treatment for COVID-19 Via Compassionate Use